Regeneron, a Tarrytown, N.Y.-based biopharmaceuticals company, has announced it has acquired the rights for two ophthalmological antibody programs from its collaborator Sanofi, Chattanooga, Tenn.-based pharmaceutical company.
The acquired antibody programs, which are in the preclinical process, target platelet derived growth factor and angiopoietin2, respectively.
Regeneron will pay Sanofi $20 million upfront for the two programs and up to $45 million for sales royalties and development milestone payments.
More Articles on Ophthalmology:
Utah Valley Eye Center Joins Effort to Provide Car in Mali
Dr. Rona Silkiss to Perform Cosmetic Oculofacial Plastic Surgery at North Bay ASC
Palmetto Eye & Laser Center Offers Alcon WaveLight Procedures
The acquired antibody programs, which are in the preclinical process, target platelet derived growth factor and angiopoietin2, respectively.
Regeneron will pay Sanofi $20 million upfront for the two programs and up to $45 million for sales royalties and development milestone payments.
More Articles on Ophthalmology:
Utah Valley Eye Center Joins Effort to Provide Car in Mali
Dr. Rona Silkiss to Perform Cosmetic Oculofacial Plastic Surgery at North Bay ASC
Palmetto Eye & Laser Center Offers Alcon WaveLight Procedures